milatuzumab humanized monoclonal antibody treatment multiple myeloma nonhodgkins lymphoma chronic lymphocytic drug first antibody entered human testing currently studied treatment multiple myeloma milatuzumab received orphan drug designation food drug administration united states treatment multiple myeloma chronic lymphocytic leukemia milatuzumab developed immunomedics inc morris plains nj usa present variety hematological tumors even solid cancers present limited amounts normal tissues widely found leukemias lymphomas vast majority multiple myeloma casescitation needed involved celltocell communication pathway critical survivalcitation needed blocked milatuzumab lead cell death attractive target drug conjugate rapid internalizing propertycitation needed preclinical studies human lymphomas myelomas naked milatuzumab milatuzumab conjugated antibodydrug conjugate adc demonstrated antilymphoma activity invivo httpsenwikipediaorgwikimilatuzumab